AMERICANN INC - ACAN STOCK NEWS

AmeriCann Inc. (OTCQB: ACAN) announced record financial results for the quarter ending December 2022. The company achieved an 11.4% increase in revenue to $734,764 compared to the same quarter in 2021, alongside a net income growth of $555,773.

CEO Tim Keogh highlighted four consecutive quarters of positive net income and plans for further expansion at the Massachusetts Cannabis Center. Adjusted EBITDA rose to $1,577,781, marking significant growth in operational efficiency. The quarter also saw remarkable annual gross margins at 98.1% and adjusted operating EBITDA margins of 45.9%.

AmeriCann Inc. (ACAN) reported significant financial growth for the fiscal year and quarter ending September 2022, achieving record revenue and net income. Annual revenue surged 44% to $2.93 million, while adjusted EBITDA increased 160% to $1.47 million. The Massachusetts Cannabis Center, with its proprietary cultivation system, played a key role in this success, generating strong cash flow and profitability. The company plans further expansion, aiming to enhance its cultivation and production capabilities significantly. With a gross margin of 98.5%, AmeriCann is poised for strong future performance.

AmeriCann Inc. (ACAN) reported record revenues for its fiscal year and quarter ending September 2022, showcasing a remarkable 44% year-over-year revenue increase, totaling over $900,000. This growth is driven by enhanced product manufacturing at their Massachusetts Cannabis Center, specifically from Building 1, a 30,000-square-foot cultivation facility. The company noted four consecutive quarters of record revenues, and significant contributions from cannabis-infused products, including the top-selling 1906 Drops and Howl's Tincture. The adult-use market in Massachusetts is projected to exceed $1.8 billion annually.

AmeriCann (ACAN) reported impressive quarterly results for Q2 2022, showcasing record high net income and revenue. Revenue surged over 36% year-over-year, reaching an increase of $213,188, with gross margins at 98.5%. July 2022 also marked an all-time monthly revenue record. The growth is attributed to operations at Building 1 of the Massachusetts Cannabis Center, fully occupied by Bask Inc. AmeriCann achieved positive Adjusted EBITDA of $438,890, an 84% rise from the previous year. The company is set to expand its operations with the upcoming Building 2, increasing cultivation infrastructure significantly.

AmeriCann Inc. (OTCQB:ACAN) reported impressive growth in its financial performance for the quarter ending June 2022, achieving a 36% increase in quarterly revenue compared to the previous year, amounting to an increase of $213,902. Monthly revenue for June 2022 also rose by 30% year-over-year. This growth is attributed to enhanced sales from its 30,000-square-foot cultivation facility in Massachusetts, which is fully occupied by a licensed operator. The cannabis market in Massachusetts is projected to reach approximately $1.8 billion annually.

AmeriCann Inc. (ACAN) reported a successful fiscal quarter ending March 31, 2022, with a 52% increase in revenue year-over-year, totaling an additional $230,021, leading to a positive net income of $24,240. The company also achieved a remarkable Adjusted EBITDA growth of 289%, reaching $297,597, with a healthy 44.6% EBITDA margin. April 2022 revenue set an all-time monthly record. This growth is primarily attributed to enhanced operations at its Massachusetts Cannabis Center, specifically Building 1, which is fully occupied by Bask Inc.

AmeriCann Inc. (ACAN) reported a remarkable 225% year-over-year revenue growth for 2021, driven by increased revenue from its Massachusetts Cannabis Center. The company's operating revenue rose significantly, fueled by the success of cannabis-infused products, particularly the 1906 branded "Drops." Notably, AmeriCann achieved positive adjusted EBITDA for all three quarters in 2021, with positive net income reported for Q3. The Massachusetts cannabis market rose to over $1.5 billion in sales, supporting AmeriCann's future growth plans for expansion in cannabis cultivation and processing.

AmeriCann (OTCQB:ACAN) announced that its Massachusetts Cannabis Center will be highlighted in Dr. Sanjay Gupta's series WEED 6: Marijuana and Autism airing on December 24, 2021. The feature aims to showcase the positive effects of cannabis on patients with severe autism. The Massachusetts Cannabis Center spans 52 acres, designed for 987,000 square feet of cultivation and processing. The initial phase includes a 30,000-square-foot greenhouse, utilizing AmeriCann's advanced Cannopy cultivation system, which reduces costs and environmental impact.

AmeriCann achieved substantial financial growth for Q3 and the fiscal year ending September 2021, posting a 303% year-over-year revenue increase to $2,028,551, with quarterly revenues up 156% to $735,076. The company reported positive net income of $42,438, and adjusted operating EBITDA rose to $370,276, marking a 50.4% EBITDA margin. Key growth is attributed to operations at its Massachusetts Cannabis Center, with further expansion planned for Building 2, estimated to add 400,000 square feet of cultivation and manufacturing space.